Zobrazeno 71 - 80
of 695
pro vyhledávání: '"Mark A Wainberg"'
Publikováno v:
Antimicrobial Drug Resistance ISBN: 9783319467160
Over the past three decades, new antiretroviral drugs have been rapidly developed and expanded for use in the clinic. Antiretroviral therapy (ART) generally combines at least three different drugs for treatment of HIV-infected patients. As more new a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ab895e2977217cf6acec6ec45400676
https://doi.org/10.1007/978-3-319-46718-4_37
https://doi.org/10.1007/978-3-319-46718-4_37
Autor:
Thibault Mesplède, Mark A. Wainberg
Publikováno v:
Viruses
Viruses, Vol 6, Iss 9, Pp 3377-3385 (2014)
Viruses, Vol 6, Iss 9, Pp 3377-3385 (2014)
Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance m
Autor:
Susan P. Colby-Germinario, Maureen Oliveira, Hongtao Xu, Daniel Rajotte, Richard Bethell, Mark A. Wainberg
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:4515-4526
A W153L substitution in HIV-1 reverse transcriptase (RT) was recently identified by selection with a novel nucleotide-competing RT inhibitor (NcRTI) termed compound A that is a member of the benzo[4,5]furo[3,2,d]pyrimidin-2-one NcRTI family of drugs.
Autor:
Nathan Osman, Melissa Wares, Peter K. Quashie, Thibault Mesplède, Diane N. Singhroy, Said Hassounah, Mark A. Wainberg, Ying-Shan Han, Kaitlin Anstett
Publikováno v:
Journal of Antimicrobial Chemotherapy. 69:2733-2740
Background The results of several clinical trials suggest that the integrase inhibitor dolutegravir may be less prone than other drugs to the emergence of HIV drug resistance mutations in treatment-naive patients. We have shown that the R263K mutatio
Publikováno v:
Journal des Anti-infectieux. 16:44-49
Resume L’inhibiteur d’integrase dolutegravir (DTG), qui a ete recemment approuve pour le traitement des personnes vivant avec le VIH, un des tres rares medicaments contre le VIH qui n’ait pas conduit a l’emergence de mutations de resistance l
Publikováno v:
AIDS. 28:813-819
Objective Among 1222 antiretroviral-naive patients who received dolutegravir (DTG) as part of first-line therapy, none has developed resistance against this compound after 48-96 weeks of follow-up. Moreover, only four occurrences of virological failu
Autor:
Susan P. Colby-Germinario, Ying-Shan Han, Maureen Oliveira, Hongtao Xu, Mark A. Wainberg, Veronica Zanichelli, Yudong Quan
Publikováno v:
Journal of Virology. 88:1536-1547
Clinical resistance to rilpivirine (RPV), a novel nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI), is associated an E-to-K mutation at position 138 (E138K) in RT together with an M184I/V mutation that confers resistance against emtricitabi
Autor:
Alonso Heredia, Mohammed N. Amin, Steven G. Deeks, Maureen Oliveira, Robert R. Redfield, Charles B. Davis, Mark A. Wainberg, Lai-Xi Wang, Nhut Le
Publikováno v:
AIDS (London, England), vol 28, iss 3
Objective The M184V mutation in the HIV-1 reverse transcriptase gene is frequent (>50%) in patients, both in resource-rich and resource-limited countries, conferring high-level resistance (>100-fold) to the cytosine analog reverse transcriptase inhib
Autor:
Zehava Grossman, Mark A. Wainberg, Isabelle Hardy, Erica E. M. Moodie, Michel Roger, Bluma G. Brenner, Ruxandra-Ilinca Ibanescu, Anne-Mieke Vandamme, David A. Stephens, Joanne Otis
Publikováno v:
AIDS (London, England). 31(5)
HIV-1 epidemics among MSM remain unchecked despite advances in treatment and prevention paradigms. This study combined viral phylogenetic and behavioural risk data to better understand underlying factors governing the temporal growth of the HIV epide
Autor:
Mark A. Wainberg, Andrew M. L. Lever
Publikováno v:
Retrovirology
It seems that a year cannot go by without some new emergent infectious disease stealing away headlines from the HIV epidemic, even though the latter continues to kill several million people each year. For example, there was justifiable concern that t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c88d73f848df4a164f9e27930236220b
https://www.repository.cam.ac.uk/handle/1810/284129
https://www.repository.cam.ac.uk/handle/1810/284129